Similarly, SEs-driven KLF5 is a key regulatory factor in ovarian cancer progression and PARPi resistance; offering potential therapeutic strategies for these patients with PARPi resistance and high KLF5 are identified (Wu Y. et al., 2023). Here, KLF5 is linked to ovarian carcinoma.